TECH
NASDAQBio-Techne Corp
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$72.11+0.30 (+0.41%)
01:30 PM07:45 PM
News · 26 weeks46+50%
2026-01-182026-07-12
Mix2490d
- Insider8(33%)
- SEC Filings6(25%)
- Other5(21%)
- Earnings2(8%)
- Analyst2(8%)
- Dividends1(4%)
Latest news
25 items- SECSEC Form DEFA14A filed by Bio-Techne CorpDEFA14A - BIO-TECHNE Corp (0000842023) (Filer)
- PRBio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein PortfolioAdvancing Scalable Reproducible Cell Therapy and Advanced Cell Culture WorkflowsNew heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolioAI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflowsEngineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturingMINNEAPOLIS, July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D
- SECBio-Techne Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - BIO-TECHNE Corp (0000842023) (Filer)
- SECSEC Form DEFA14A filed by Bio-Techne CorpDEFA14A - BIO-TECHNE Corp (0000842023) (Filer)
- SECBio-Techne Corp filed SEC Form 8-K: Regulation FD Disclosure, Leadership Update, Financial Statements and Exhibits8-K - BIO-TECHNE Corp (0000842023) (Filer)
- PRMerck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences MarketsPurchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion)Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closingU.S.-based Bio-Techne to bring portfolio with industry-leading multi-omics offering, analytical technologies and integrated workflow solutions across the scientific journeyWould deliver on growth agenda of Merck KGaA, Darmstadt, Germany, by expanding presence in high-growth, next-generation life sciences markets and further strengthening the position as a leader along the full life science value chainWould add complementary strength
- ANALYSTPiper Sandler initiated coverage on Bio-Techne with a new price targetPiper Sandler initiated coverage of Bio-Techne with a rating of Neutral and set a new price target of $65.00
- INSIDERPresident - Diag & Spatial Bi Crouse Steven C. converted options into 600 shares and covered exercise/tax liability with 216 shares, increasing direct ownership by 6% to 6,761 units (SEC Form 4)4 - BIO-TECHNE Corp (0000842023) (Issuer)
- PRBio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar CharacterizationNew integrated workflow combines icIEF fractionation and mass photometryEnables direct characterization of aggregation and size within icIEF-resolved charge variantsFour-hour workflow reduces development risk and accelerates biosimilar manufacturingMINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focu
- SECSEC Form SD filed by Bio-Techne CorpSD - BIO-TECHNE Corp (0000842023) (Filer)
- ANALYSTRBC Capital Mkts resumed coverage on Bio-Techne with a new price targetRBC Capital Mkts resumed coverage of Bio-Techne with a rating of Outperform and set a new price target of $62.00
- INSIDERDirector Herr Amy E. sold $320,386 worth of shares (6,636 units at $48.28) and exercised 6,636 shares at a strike of $47.60 (SEC Form 4)4 - BIO-TECHNE Corp (0000842023) (Issuer)
- INSIDERCFO Hippel James covered exercise/tax liability with 56,955 shares and exercised 62,000 shares at a strike of $47.60, increasing direct ownership by 3% to 153,670 units (SEC Form 4)4 - BIO-TECHNE Corp (0000842023) (Issuer)
- INSIDERSVP - General Counsel Bohnen Shane exercised 8,400 shares at a strike of $47.60 and covered exercise/tax liability with 7,055 shares, increasing direct ownership by 23% to 7,249 units (SEC Form 4)4 - BIO-TECHNE Corp (0000842023) (Issuer)
- INSIDERChief Executive Officer Kelderman Kim exercised 26,692 shares at a strike of $47.60 and covered exercise/tax liability with 23,951 shares, increasing direct ownership by 4% to 65,799 units (SEC Form 4)4 - BIO-TECHNE Corp (0000842023) (Issuer)
- PRBio-Techne Declares DividendMINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio–Techne Corporation (NASDAQ:TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfo
- PRBio-Techne Releases Third Quarter Fiscal 2026 ResultsMINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2026.Third Quarter FY2026 HighlightsReported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipmentsGAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56Large pharma delivered the sixth consecutive quarter of double‑digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low‑single‑digit growthGrowth vectors performed well, with mid‑single‑digit growth in Proteomic Analy
- SECSEC Form 10-Q filed by Bio-Techne Corp10-Q - BIO-TECHNE Corp (0000842023) (Filer)
- SECSEC Form SCHEDULE 13G filed by Bio-Techne CorpSCHEDULE 13G - BIO-TECHNE Corp (0000842023) (Subject)
- SECBio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - BIO-TECHNE Corp (0000842023) (Filer)
- INSIDERPresident - Diag & Spatial Bi Crouse Steven C. converted options into 794 shares and covered exercise/tax liability with 311 shares, increasing direct ownership by 8% to 6,337 units (SEC Form 4)4 - BIO-TECHNE Corp (0000842023) (Issuer)
- PRBio-Techne to Present at the Bank of America Securities 2026 Global Healthcare ConferenceMINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026, at 9:20 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio‑Techne Corporation (NASDAQ:TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents
- INSIDERChief Executive Officer Kelderman Kim converted options into 11,344 shares and covered exercise/tax liability with 1,363 shares, increasing direct ownership by 19% to 63,058 units (SEC Form 4)4 - BIO-TECHNE Corp (0000842023) (Issuer)
- INSIDERCFO Hippel James covered exercise/tax liability with 56,097 shares and converted options into 62,000 shares, increasing direct ownership by 4% to 148,625 units (SEC Form 4)4 - BIO-TECHNE Corp (0000842023) (Issuer)
- INSIDERSEC Form 4 filed by Kelderman Kim4 - BIO-TECHNE Corp (0000842023) (Issuer)
TECH FAQ
7 questionsWhat does Bio-Techne Corp do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers...Where does TECH stock trade?
Bio-Techne Corp (TECH) is listed on NASDAQ.What sector and industry is TECH in?
Bio-Techne Corp operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.Does TECH pay a dividend?
TECH's most recent ex-dividend date was 2026-05-18 with a cash dividend of $0.08 per share. No future ex-date is on file yet.What are analysts saying about TECH?
Bio-Techne Corp has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral on 2026-06-11.What companies are similar to TECH?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare TECH side-by-side with any of them on Quantisnow.How can I track TECH on Quantisnow?
Quantisnow aggregates Bio-Techne Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TECH to receive live email and push alerts on every new disclosure.